Literature DB >> 28677818

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Maria Winqvist1,2, Marzia Palma1,2, Kia Heimersson2, Håkan Mellstedt2, Anders Österborg1,2, Jeanette Lundin1,2.   

Abstract

Entities:  

Keywords:  PDCD1 (PD-1); T cells; alemtuzumab; chronic lymphocytic leukaemia; ibrutinib

Mesh：

Substances：

Year:  2017        PMID： 28677818     DOI： 10.1111/bjh.14836

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.

Authors:  Jeanette Lundin; Tom A Mulder; Magdalena Kättström; Tove Wästerlid; Anders Uddevik; Håkan Mellstedt; Kia Heimersson; Lotta Hansson; Marzia Palma; Anders Österborg
Journal:  EJHaem       Date:  2021-07-14

2.  Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.

Authors:  Viktoria Fuhr; Ehsan Vafadarnejad; Oliver Dietrich; Panagiota Arampatzi; Angela Riedel; Antoine-Emmanuel Saliba; Andreas Rosenwald; Hilka Rauert-Wunderlich
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.